Synthesis and biological characterisation of [3H]BBL454, a new CCK2 selective radiolabelled agonist displaying original pharmacological properties

Self-Organized Ureido Substituted Diacetylenic Organogel. Photopolymerization of One-Dimensional Supramolecular Assemblies to Give Conjugated Nanofibers

The introduction of the urea function as structure directing agent of diacetylene organogels (DA-OGs) has been achieved. Despite the urea function being one of the most frequently used structure directing agents for the formation of organogels, it has never been exploited in the fabrication and photopolymerization of DA-OGs. The self-association of ureas involving two hydrogen bonds is much stronger than that of urethanes or amides, and the resulting supramolecular assemblies are completely insoluble. In this context, 1,1'-(hexa-2,4-diyne-1,6-diyl)bis(3-(10-(triethoxysilyl)decyl)urea) 2 was synthesized. Compound 2 was soluble owing to the triethoxysilane function that we recently used in the fabrication of a silylated bis-urea-stilbene organogel. It formed an organogel, and its photopolymerization was studied in cyclohexane. The loss of the gel state and the formation of a red solution resulting from the polymerization were found to be the result of the constraints introduced by the urea function in close vicinity to the polymerizable function. To obtain an ureido substituted diacetylenic organogelator affording a blue highly conjugated polydiacetylene (PDA) without a sol-gel transition, a propylene spacer was introduced to move the urea function away from the polymerizable function (derivative 3). The thermochromism exhibited by the latter in the solid state was studied. Using the same setup and the same sample, UV-vis and FTIR spectra were simultaneously recorded as a function of the temperature to highlight a relation between color changes and urea association mode changes. The data showed that the reversible thermochromic transition must be associated with a reversible supramolecular modification and, conversely, that irreversible chromic transitions are the result of irreversible structural modifications. The chromic effects of the acidic hydrolysis-polycondensation of the trialkoxysilyl groups to form a siloxane network were studied on a thin film of 3. In the same way, solvent effects on the color of the organogels of 3 were also investigated. Correlations could be established between the different stimuli. These results provide a deeper understanding of the precise molecular mechanism of the blue to red transition and of the reversibility of the purple to red transition generally encountered in PDA thermochromism.

Application of azide-alkyne cycloaddition 'click chemistry' for the synthesis of Grb2 SH2 domain-binding macrocycles

Copper (I) promoted [3+2] Huisgen cycloaddition of azides with terminal alkynes was used to prepare triazole-containing macrocycles based on the Grb2 SH2 domain-binding motif, 'Pmp-Ac(6)c-Asn', where Pmp and Ac(6)c stand for 4-phosphonomethylphenylalanine and 1-aminocyclohexanecarboxylic acid, respectively. When cycloaddition reactions were conducted at 1mM substrate concentrations, cyclization of monomeric units occurred. At 2mM substrate concentrations the predominant products were macrocyclic dimers. In Grb2 SH2 domain-binding assays the monomeric (S)-Pmp-containing macrocycle exhibited a K(d) value of 0.23microM, while the corresponding dimeric macrocycle was found to have greater than 50-fold higher affinity. The open-chain dimer was also found to have affinity equal to the dimeric macrocycle. This work represents the first application of 'click chemistry' to the synthesis of SH2 domain-binding inhibitors and indicates its potential utility.

New CCK2 agonists confirming the heterogeneity of CCK2 receptors: characterisation of BBL454

Pharmacological studies were undertaken with a new series of cholecystokinin(2) CCK(2) agonists in order to assign to them a CCK(2A) or CCK(2B) pharmacological profile. The open-field test was chosen as the discrimination test of CCK(2B) agonists. The most interesting agonist, BBL454 (0.03-300 microg/kg) induced hyperactivity which was blocked by a CCK(2) antagonist, the D1 antagonist SCH23390, the delta-opioid antagonist naltrindole, but not a CCK(1) antagonist. All compounds active in the open-field test are characterised by a common structural feature, -COCH(2)CO-Trp-NMeNle-Asp-Phe-NH(2), whereas inactive compounds do not possess such a motive. Therefore, this feature can be considered crucial for CCK(2B) activity. BBL454 (0.03-3 microg/kg) improved memory in a two-trial memory test while it was very weakly active on the peripheral CCK(2) receptor, and did not evoke anxiogenic effects in the plus-maze test. The synthesis of BBL454 is simple, its minimal active dose is 30 ng/kg and no "bell-shaped" responses were observed. These results suggest that BBL454 could be considered to be the new CCK(2B) reference agonist.